摘要
目的:探讨黄芪注射液联合左卡尼汀治疗柯萨奇病毒B3病毒性心肌炎(CVB3-VMC)的效果。方法:选取2017年5月-2020年6月我院CVB3-VMC患者114例,按照随机数字表法分为研究组和对照组,每组57例。对照组予以左卡尼汀,研究组予以黄芪注射液配合左卡尼汀,均治疗4周。比较两组疗效、不良反应与治疗前后细胞免疫功能,IL-35以及sIL-2R炎性因子水平。结果:治疗4周后研究组总有效率高于对照组(92.98%vs 73.68%,P<0.05);研究组血清CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、NK细胞、IL-35水平均高于对照组且sIL-2R水平低于对照组(P<0.05);两组患者不良反应发生率差异无统计学意义(P>0.05)。结论:黄芪注射液联合左卡尼汀治疗CVB3-VMC效果显著,且安全性较好。
Objective:To explore the effect of Huangqi injection combined with levocarnitine on viral myocarditis caused by Coxsackie virus B3(CVB3-VMC).Methods:A total of 114 patients with CVB3-VMC in our hospital from May 2017 to June 2020 were selected and divided into study group and control group based on the random number table,with 57 cases in each group.The control group was treated with levocarnitine while the study group was treated with Huangqi injection combined with levocarnitine.Both groups were treated for 4 weeks.The efficacy,adverse drug reaction(ADR),and cellular immune function,levels of IL-35 as well as sIL-2R inflammatory factors before and after treatment were compared between the two groups.Results:After 4 weeks of treatment,the total effective rate of the study group was significantly higher than that of control group(92.98%vs 73.68%,P<0.05).The levels of serum CD3^(+),CD4^(+),CD4^(+)/CD8^(+),NK cells and levels of IL-35 in the study group were higher than those of the control group and the level of serum sIL-2R was significantly lower than that of the control group(P<0.05).There was no significant difference in the incidence of ADR between the two groups(P>0.05).Conclusion:Huangqi injection combined with levocarnitine had a significant effect on CVB3-VMC with good safety.
作者
王书芬
倪猛
冀叶
WANG Shu-fen;NI Meng;JI Ye(Department of Pharmacy,Nanyang Central Hospital,Nanyang 473000,China;Department of Gastroenterology,Nanyang Central Hospital,Nanyang 473000,China;Department of Oncology,Nanyang Central Hospital,Nanyang 473000,China)
出处
《中国药物应用与监测》
CAS
2022年第2期69-72,共4页
Chinese Journal of Drug Application and Monitoring
基金
南阳市科学技术局项目(192102310326)。
作者简介
王书芬,女,主管药师,研究方向:临床药学。E-mail:wshufen69@sina.com。
